Medicare and GLP-1 Coverage
Why Medicare historically excluded weight-loss drugs — and the indication-based side doors opening since.
Medicare Part D has excluded "weight loss" drugs by statute since its creation — a 2003-era judgment colliding with 2020s medicine. The consequential loopholes are indication-based: once semaglutide gained cardiovascular-risk approval (SELECT) and tirzepatide gained sleep-apnea approval, Medicare plans could cover those uses, and diabetes-indicated siblings (Ozempic, Mounjaro) were always coverable for diabetes.
Policy here moves annually — legislative proposals to lift the exclusion recur, and plan-level implementation varies — so current-year verification with your specific Part D plan beats any article, including this one. For beneficiaries outside the covered indications, savings cards are federally off-limits, leaving self-pay programs and the occasional supplemental-plan quirk as the practical lanes. We're not responsible for third-party coverage decisions; your plan's documents govern.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Medicare and GLP-1 Coverage? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment